Publicacións (22) Publicacións nas que participase algún/ha investigador/a

2014

  1. A new non-expressed allele HLA-A*03:168N, identified by serological and sequence-based typing in a voluntary Norwegian hematopoietic stem cell donor

    Tissue Antigens, Vol. 83, Núm. 3, pp. 195-196

  2. A novel mutation in adamts13 of a child with upshaw-schulman syndrome

    Thrombosis and Haemostasis

  3. An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation

    Frontiers in Oncology, Vol. 4 JUN

  4. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

    Tumori, Vol. 100, Núm. 2, pp. 225-231

  5. Diagnosis of inherited von Willebrand disease: Comparison of two methodologies and analysis of the discrepancies

    Haemophilia, Vol. 20, Núm. 4, pp. 559-567

  6. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

    American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211

  7. Enfermedad pulmonar intersticial difusa como primera manifestación de macroglobulinemia de Waldenström: descripción de un caso y revisión de la literatura

    Archivos de Bronconeumologia, Vol. 50, Núm. 4, pp. 151-153

  8. Espectro clínico de la Enfermedad de Castleman

    Galicia Clínica, Vol. 75, Núm. 4, pp. 191-194

  9. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

    The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111

  10. Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: Results from a collaborative study

    Orphanet Journal of Rare Diseases, Vol. 9, Núm. 1

  11. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?

    Blood, Vol. 124, Núm. 12, pp. 1887-1893

  12. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients

    Annals of Hematology, Vol. 93, Núm. 2, pp. 299-307

  13. Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain

    Journal of Medical Economics, Vol. 17, Núm. 6, pp. 435-441

  14. Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): A short review

    Thrombosis Research, Vol. 134, Núm. 6, pp. 1171-1175

  15. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial

    British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336

  16. Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma

    Leukemia Research, Vol. 38, Núm. 7, pp. 737-743

  17. Mitochondrial dysfunction promotes and aggravates the inflammatory response in normal human synoviocytes

    Rheumatology (United Kingdom), Vol. 53, Núm. 7, pp. 1332-1343

  18. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning

    Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 6, pp. 890-895

  19. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

    Haematologica, Vol. 99, Núm. 10, pp. 1632-1637

  20. Simplification of risk stratification for splenic marginal zone lymphoma: A point-based score for practical use

    Leukemia and Lymphoma